Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 8/20 | 0.36 |
| ▸ | FNTB | P49356 | 8/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578563 | 0.85 | FNTA (0.36) | HTTCYP11B1CYP11B2KCNA5MAPT | |
| SCHEMBL5227451 | 0.82 | HTT (0.46) | HTTCYP11B1CYP11B2KCNA5MAPT | |
| SCHEMBL3571215 | 0.79 | HTT (0.58) | HTTCYP11B1CYP11B2KCNA5MAPT | |
| SCHEMBL3571192 | 0.78 | HTT (0.57) | HTTCYP11B1CYP11B2KCNA5MAPT | |
| SCHEMBL3568025 | 0.76 | HTT (0.50) | HTTCYP11B1CYP11B2KCNA5MAPT | |
| SCHEMBL6906268 | 0.73 | CYP11B1 (0.53) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL3978875 | 0.71 | CYP11B1 (0.38) | CYP11B1CYP11B2KDM4EGAARAB9A | |
| SCHEMBL8812550 | 0.69 | CYP19A1 (0.39) | CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL7714943 | 0.69 | CYP11B1 (0.38) | CYP11B1CYP11B2FNTAFNTB | |
| SCHEMBL1097391 | 0.67 | KCNA5 (0.31) | KCNA5L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| EP-1537114-B1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | CYP11B1, CYP27A1, CYP17A1 | HTT 4875/4885CYP11B1 1/4885CYP11B2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.